Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.

@article{LastresBecker2016RepurposingTN,
  title={Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.},
  author={Isabel Lastres-Becker and {\'A}ngel Juan Garc{\'i}a-Yag{\"u}e and Robert H. Scannevin and Mar{\'i}a Jos{\'e} Casarejos and Sebastian K{\"u}gler and Alberto R{\'a}bano and Antonio Cuadrado},
  journal={Antioxidants & redox signaling},
  year={2016},
  volume={25 2},
  pages={
          61-77
        }
}
AIMS This preclinical study was aimed at determining whether pharmacological targeting of transcription factor NRF2, a master controller of many homeostatic genes, might provide a disease-modifying therapy in the animal model of Parkinson's disease (PD) that best reproduces the main hallmark of this pathology, that is, α-synucleinopathy, and associated events, including nigral dopaminergic cell death, oxidative stress, and neuroinflammation. RESULTS Pharmacological activation of NRF2 was… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 77 REFERENCES

Similar Papers

Loading similar papers…